Our data are consistent with studies showing that instead multiple metabolic pathways must be targeted to overcome metabolic flexibility of cancer cells, including a previous in vivo study in lung cancer showing that tumors that are insensitive to inhibition of glycolysis or GLS alone, are sensitive to the combination of both glycolysis and GLS inhibition (33–35). The gene discussed is GLS; the disease is lung cancer.